Neuronetics’ Initial Public Offering Raises $107.5 Million

On July 2, 2018, Neuronetics, Inc. (Neuronetics) announced that its initial public offering (IPO) resulted in $107.5 million in aggregate gross proceeds. Founded in 2003, Neuronetics' markets the Federal Drug Administration (FDA)-cleared NeuroStar® Advanced Therapy System (NeuroStar), a noninvasive transcranial magnetic stimulation (TMS) treatment that sends magnetic fields into the brain to stimulate nerve cells, with the goal of improving symptoms of major depressive disorder. A total of 6,325,000 shares of its common stock was offered. The initial public offering included the exercise in full of the underwriters’ option to purchase 825,000 additional shares of . . .